Sverre Sandberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2165440/publications.pdf

Version: 2024-02-01

303 papers

8,109 citations

43 h-index

61984

79698 73 g-index

322 all docs 322 docs citations

times ranked

322

5332 citing authors

#	Article	IF	CITATIONS
1	Fur glowing under ultraviolet: $\langle i \rangle$ in situ $\langle i \rangle$ analysis of porphyrin accumulation in the skin appendages of mammals. Integrative Zoology, 2023, 18, 15-26.	2.6	5
2	The total prevalence of diagnosed diabetes and the quality of diabetes care for the adult population in Salten, Norway. Scandinavian Journal of Public Health, 2022, 50, 161-171.	2.3	4
3	European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates for serum thyroid biomarkers based on weekly samplings from 91 healthy participants. Clinical Chemistry and Laboratory Medicine, 2022, 60, 523-532.	2.3	21
4	The European Biological Variation Study (EuBIVAS): a summary report. Clinical Chemistry and Laboratory Medicine, 2022, 60, 505-517.	2.3	40
5	Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study. Clinical Chemistry and Laboratory Medicine, 2022, 60, 543-552.	2.3	19
6	Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of serum zinc, copper and selenium. Clinical Chemistry and Laboratory Medicine, 2022, 60, 479-482.	2.3	7
7	Critical appraisal and meta-analysis of biological variation estimates for kidney related analytes. Clinical Chemistry and Laboratory Medicine, 2022, 60, 469-478.	2.3	15
8	Biological variation of serum insulin: updated estimates from the European Biological Variation Study (EuBIVAS) and meta-analysis. Clinical Chemistry and Laboratory Medicine, 2022, 60, 518-522.	2.3	6
9	Within- and between-subject biological variation data for serum zinc, copper and selenium obtained from 68 apparently healthy Turkish subjects. Clinical Chemistry and Laboratory Medicine, 2022, 60, 533-542.	2.3	8
10	Personalized reference intervals: Using estimates of within-subject or within-person biological variation requires different statistical approaches. Clinica Chimica Acta, 2022, 524, 201-202.	1.1	9
11	Biological variation estimates of thyroid related measurands– meta-analysis of BIVAC compliant studies. Clinical Chemistry and Laboratory Medicine, 2022, 60, 483-493.	2.3	15
12	Long-term within- and between-subject biological variation of 29 routine laboratory measurands in athletes. Clinical Chemistry and Laboratory Medicine, 2022, 60, 618-628.	2.3	5
13	A national surveillance program for evaluating new reagent lots in medical laboratories. Clinical Chemistry and Laboratory Medicine, 2022, 60, 351-360.	2.3	6
14	Dr Per Hyltoft Petersen: an appreciation. Clinical Chemistry and Laboratory Medicine, 2022, 60, 299-300.	2.3	0
15	Critical review and meta-analysis of biological variation estimates for tumor markers. Clinical Chemistry and Laboratory Medicine, 2022, 60, 494-504.	2.3	13
16	Biological variation– eight years after the 1st Strategic Conference of EFLM. Clinical Chemistry and Laboratory Medicine, 2022, 60, 465-468.	2.3	8
17	Point-of-care testing in primary healthcare: a scoring system to determine the frequency of performing internal quality control. Clinical Chemistry and Laboratory Medicine, 2022, 60, 740-747.	2.3	5
18	Lot-to-lot reagent verification: challenges and possible solutions. Clinical Chemistry and Laboratory Medicine, 2022, 60, 675-680.	2.3	18

#	Article	IF	CITATIONS
19	Porphyria cutanea tarda and patterns of long-term sick leave and disability pension: a 24-year nationwide matched-cohort study. Orphanet Journal of Rare Diseases, 2022, 17, 72.	2.7	2
20	Measurement uncertainty for practical use. Clinica Chimica Acta, 2022, 531, 352-360.	1.1	8
21	Cohort profile: Outcomes & Dulti-morbidity In Type 2 diabetes (OMIT) – a national registry-based observational cohort with focus on care and treatment of key high-risk groups in Norway. BMJ Open, 2022, 12, e054840.	1.9	2
22	Personalized reference intervals: from theory to practice. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 501-516.	6.1	9
23	Setting minimum clinical performance specifications for tests based on disease prevalence and minimum acceptable positive and negative predictive values: Practical considerations applied to COVID-19 testing. Clinical Biochemistry, 2021, 88, 18-22.	1.9	5
24	Personalized Reference Intervals in Laboratory Medicine: A New Model Based on Within-Subject Biological Variation. Clinical Chemistry, 2021, 67, 374-384.	3.2	45
25	Biological Variation of Cardiac Troponins in Health and Disease: A Systematic Review and Meta-analysis. Clinical Chemistry, 2021, 67, 256-264.	3.2	21
26	Performance and user-friendliness of the rapid antigen detection tests QuickVue Dipstick Strep A test and DIAQUICK Strep A Blue Dipstick for pharyngotonsilitis caused by Streptococcus pyogenes in primary health care. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 549-558.	2.9	3
27	Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators. International Journal of Molecular Sciences, 2021, 22, 675.	4.1	25
28	Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection. BMJ, The, 2021, 372, n568.	6.0	18
29	Factors associated with treatment in primary versus specialist care: A populationâ€based study of people with type 2 and type 1 diabetes. Diabetic Medicine, 2021, 38, e14580.	2.3	5
30	High adherence to recommended diabetes followâ€up procedures by general practitioners is associated with lower estimated cardiovascular risk. Diabetic Medicine, 2021, 38, e14586.	2.3	6
31	Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran. Journal of Inherited Metabolic Disease, 2021, 44, 961-971.	3.6	34
32	Variation between general practitioners in type 2 diabetes processes of care. Primary Care Diabetes, 2021, 15, 495-501.	1.8	8
33	Evaluation of 32 rapid tests for detection of antibodies against SARS-CoV-2. Clinica Chimica Acta, 2021, 519, 133-139.	1.1	7
34	The European Biological Variation Study (EuBIVAS): Biological Variation Data for Coagulation Markers Estimated by a Bayesian Model. Clinical Chemistry, 2021, 67, 1259-1270.	3.2	14
35	Factors associated with potential over―and undertreatment of hyperglycaemia and annual measurement of HbA 1c in type 2 diabetes in norwegian general practice. Diabetic Medicine, 2021, 38, e14500.	2.3	5
36	Setting analytical performance specifications using HbA1c as a model measurand. Clinica Chimica Acta, 2021, 523, 407-414.	1.1	6

#	Article	IF	CITATIONS
37	Biological variation of venous acid-base status measurands in athletes. Clinica Chimica Acta, 2021, 523, 497-503.	1.1	3
38	Factors associated with glycaemic control in adults with Type 1 diabetes: a registryâ€based analysis including 7601 individuals from 34 centres in Norway. Diabetic Medicine, 2020, 37, 828-837.	2.3	5
39	Variation in the achievement of HbA _{1c} , blood pressure and <scp>LDL</scp> cholesterol targets in type 2 diabetes in general practice and characteristics associated with risk factor control. Diabetic Medicine, 2020, 37, 1471-1481.	2.3	6
40	EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology, 2020, 71, 1546-1558.	7.3	103
41	A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria. Molecular Therapy, 2020, 28, 677-689.	8.2	10
42	Performance of Afinion HbA1c measurements in general practice as judged by external quality assurance data. Clinical Chemistry and Laboratory Medicine, 2020, 58, 588-596.	2.3	2
43	Biological variation of morning serum cortisol: Updated estimates from the European biological variation study (EuBIVAS) and meta-analysis. Clinica Chimica Acta, 2020, 509, 268-272.	1.1	12
44	Spirometry in chronic obstructive pulmonary disease in Norwegian general practice. BMC Family Practice, 2020, 21, 235.	2.9	5
45	European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates for serum biointact parathyroid hormone based on weekly samplings from 91 healthy participants. Annals of Translational Medicine, 2020, 8, 855-855.	1.7	10
46	Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study. Health and Quality of Life Outcomes, 2020, 18, 84.	2.4	6
47	Sick leave, disability, and mortality in acute hepatic porphyria: a nationwide cohort study. Orphanet lournal of Bare Diseases 2020 1545 (EuBIVAS): within- and between-subject biological variation	2.7	8
48	estimates of î²-isomerized C-terminal telopeptide of type I collagen (î²-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein—a cooperation between the EFLM Working Group of Clinical Variation and the International Osteoporosis Foundation-International 2020, 31	3.1	31
49	Federation of Clinical Chemistry Committee on Bone Metabol. Osteoporosis International, 2020, 31, 146 Analytical Performance Specifications for Lipoprotein(a), Apolipoprotein B-100, and Apolipoprotein A-I Using the Biological Variation Model in the EuBIVAS Population. Clinical Chemistry, 2020, 66, 727-736.	3.2	17
50	Critical appraisal and meta-analysis of biological variation studies on glycosylated albumin, glucose and HbA _{1c} . Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1,	0.2	6
51	The European Biological Variation Study (EuBIVAS): weekly biological variation of cardiac troponin I estimated by the use of two different high-sensitivity cardiac troponin I assays. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1741-1747.	2.3	25
52	Availability and analytical quality of hemoglobin A _{1c} point-of-care testing in general practitioners' offices are associated with better glycemic control in type 2 diabetes. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1349-1356.	2.3	14
53	Evaluación crÃŧica y meta-análisis de estudios de variación biológica para albúmina glicosilada, glucosa y HbA _{1c} . Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.2	1
54	Quality of Warfarin Therapy and Quality of Life are Improved by Self-Management for Two Years. Thrombosis and Haemostasis, 2019, 119, 1632-1641.	3.4	9

#	Article	IF	CITATIONS
55	Concentration of fibrin monomer in pregnancy and during the postpartum period. Annals of Clinical Biochemistry, 2019, 56, 692-700.	1.6	4
56	Self-efficacy and self-management strategies in acute intermittent porphyria. BMC Health Services Research, 2019, 19, 444.	2.2	6
57	A Bayesian Approach to Biological Variation Analysis. Clinical Chemistry, 2019, 65, 995-1005.	3.2	15
58	FRI-442-Acute hepatic porphyria disease manifestations and daily life impacts in EXPLORE international, prospective, natural history study. Journal of Hepatology, 2019, 70, e589-e590.	3.7	6
59	Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of 20 haematological parameters. Clinical Chemistry and Laboratory Medicine, 2019, 58, 25-32.	2.3	40
60	Handling of hemolyzed serum samples in clinical chemistry laboratories: the Nordic hemolysis project. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1699-1711.	2.3	8
61	European Biological Variation Study (EuBIVAS): Within- and Between-Subject Biological Variation Data for 15 Frequently Measured Proteins. Clinical Chemistry, 2019, 65, 1031-1041.	3.2	39
62	Biological variation data for lipid cardiovascular risk assessment biomarkers. A systematic review applying the biological variation data critical appraisal checklist (BIVAC). Clinica Chimica Acta, 2019, 495, 467-475.	1.1	27
63	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. Genetics in Medicine, 2019, 21, 2605-2613.	2.4	16
64	Pre-analytical practices for routine coagulation tests in European laboratories. A collaborative study from the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM). Clinical Chemistry and Laboratory Medicine, 2019, 57, 1511-1521.	2.3	6
65	Setting clinical performance specifications to develop and evaluate biomarkers for clinical use. Annals of Clinical Biochemistry, 2019, 56, 527-535.	1.6	23
66	FRI-440-Management of acute hepatic porphyria attacks in europe and united states: EXPLORE international, prospective, natural history study. Journal of Hepatology, 2019, 70, e588.	3.7	0
67	Commutability of a Whole-Blood External Quality Assessment Material for Point-of-Care C-Reactive Protein, Glucose, and Hemoglobin Testing. Clinical Chemistry, 2019, 65, 791-797.	3.2	10
68	Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study. Orphanet Journal of Rare Diseases, 2019, 14, 77.	2.7	15
69	Ethnic and gender differences in the management of type 2 diabetes: a cross-sectional study from Norwegian general practice. BMC Health Services Research, 2019, 19, 904.	2.2	8
70	Systematic review of the biological variation data for diabetes related analytes. Clinica Chimica Acta, 2019, 488, 61-67.	1.1	32
71	Population, general practitioner and practice characteristics are associated with screening procedures for microvascular complications in Type 2 diabetes care in Norway. Diabetic Medicine, 2019, 36, 1431-1443.	2.3	9
72	Exploring the relationship between coronary heart disease and type 2 diabetes: a cross-sectional study of secondary prevention among diabetes patients. BJGP Open, 2019, 3, bjgpopen18X101636.	1.8	13

#	Article	IF	Citations
73	Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference. Laboratornaya Sluzhba, 2019, 8, 93.	0.2	4
74	Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver. Journal of Internal Medicine, 2018, 284, 78-91.	6.0	88
75	Within-subject and between-subject biological variation estimates of 21 hematological parameters in 30 healthy subjects. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1309-1318.	2.3	51
76	Hemolysis interference studies: freeze method should be used in the preparation of hemolyzed samples. Clinical Chemistry and Laboratory Medicine, 2018, 56, e220-e222.	2.3	10
77	Quality Control of Norwegian Pharmacy HbA1c Testing: A Modest Beginning. Journal of Diabetes Science and Technology, 2018, 12, 753-761.	2.2	4
78	Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1297-1308.	2.3	8
79	Valid analytical performance specifications for combined analytical bias and imprecision for the use of common reference intervals. Annals of Clinical Biochemistry, 2018, 55, 612-615.	1.6	3
80	Harmonization initiatives in the generation, reporting and application of biological variation data. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1629-1636.	2.3	33
81	The Biological Variation Data Critical Appraisal Checklist: A Standard for Evaluating Studies on Biological Variation. Clinical Chemistry, 2018, 64, 501-514.	3.2	152
82	The use of error and uncertainty methods in the medical laboratory. Clinical Chemistry and Laboratory Medicine, 2018, 56, 209-219.	2.3	66
83	Harmonization activities of Noklus – a quality improvement organization for point-of-care laboratory examinations. Clinical Chemistry and Laboratory Medicine, 2018, 57, 106-114.	2.3	17
84	Are general practitioners characteristics associated with the quality of type 2 diabetes care in general practice? Results from the Norwegian ROSA4 study from 2014. Scandinavian Journal of Primary Health Care, 2018, 36, 170-179.	1.5	13
85	Impact of acute hepatic porphyrias on quality of life and work loss: An analysis of EXPLORE natural history study. Journal of Hepatology, 2018, 68, S622.	3.7	0
86	EXPLORE: A prospective, multinational natural history study of patients with acute hepatic porphyria with recurrent attacks. Journal of Hepatology, 2018, 68, S80-S81.	3.7	2
87	The EuBIVAS: Within- and Between-Subject Biological Variation Data for Electrolytes, Lipids, Urea, Uric Acid, Total Protein, Total Bilirubin, Direct Bilirubin, and Glucose. Clinical Chemistry, 2018, 64, 1380-1393.	3.2	75
88	An overview of EFLM harmonization activities in Europe. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1591-1597.	2.3	7
89	Providing Correct Estimates of Biological Variation—Not an Easy Task. The Example of S100-β Protein and Neuron-Specific Enolase. Clinical Chemistry, 2018, 64, 1537-1539.	3.2	19
90	Trends in healthcare utilization in the United States and Europe associated with patient with acute hepatic porphyria with recurrent attacks in EXPLORE: A prospective, multinational natural history study of patients with acute hepatic porphyria. Journal of Hepatology, 2018, 68, S622-S623.	3.7	0

#	Article	IF	CITATIONS
91	Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer. Clinica Chimica Acta, 2018, 486, 185-191.	1.1	37
92	Risk assessment and HbA1c measurement in Norwegian community pharmacies to identify people with undiagnosed type 2 diabetes $\hat{a} \in A$ feasibility study. PLoS ONE, 2018, 13, e0191316.	2.5	7
93	Practical guide for identifying unmet clinical needs for biomarkers. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2018, 29, 129-137.	0.7	19
94	Glycemic control and complications in patients with type 1 diabetesÂ-Âa registry-based longitudinal study of adolescents and young adults. Pediatric Diabetes, 2017, 18, 188-195.	2.9	62
95	Estimates of Within-Subject Biological Variation of Protein C, Antithrombin, Protein S Free, Protein S Activity, and Activated Protein C Resistance in Pregnant Women. Clinical Chemistry, 2017, 63, 898-907.	3.2	17
96	To report or not to report: a proposal on how to deal with altered test results in hemolytic samples. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1109-1111.	2.3	25
97	Biological variation: Evaluation of methods for constructing confidence intervals for estimates of within-person biological variation for different distributions of the within-person effect. Clinica Chimica Acta, 2017, 468, 166-173.	1.1	12
98	Improving quality in the preanalytical phase through innovation, on behalf of the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for Preanalytical Phase (WG-PRE). Clinical Chemistry and Laboratory Medicine, 2017, 55, 489-500.	2.3	41
99	A pragmatic approach to sample acceptance and rejection. Clinical Biochemistry, 2017, 50, 579-581.	1.9	23
100	Biological Variation Estimates Obtained from 91 Healthy Study Participants for 9 Enzymes in Serum. Clinical Chemistry, 2017, 63, 1141-1150.	3.2	51
101	American Liver Guidelines and Cutoffs for "Normal―ALT: A Potential for Overdiagnosis. Clinical Chemistry, 2017, 63, 1196-1198.	3.2	25
102	Strategies to define performance specifications in laboratory medicine: 3 years on from the Milan Strategic Conference. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1849-1856.	2.3	56
103	Pre- and post-test probabilities of venous thromboembolism and diagnostic accuracy of D-dimer, estimated by European clinicians working in emergency departments. Thrombosis Research, 2017, 159, 19-23.	1.7	8
104	The EuBIVAS Project: Within- and Between-Subject Biological Variation Data for Serum Creatinine Using Enzymatic and Alkaline Picrate Methods and Implications for Monitoring. Clinical Chemistry, 2017, 63, 1527-1536.	3.2	66
105	Acute hepatic porphyria and cancer risk: a nationwide cohort study. Journal of Internal Medicine, 2017, 282, 229-240.	6.0	32
106	Warfarin monitoring in nursing homes assessed by case histories. Do recommendations and electronic alerts affect judgements?. Scandinavian Journal of Primary Health Care, 2017, 35, 299-306.	1.5	3
107	Type 2 diabetes in general practice in Norway 2005–2014: moderate improvements in risk factor control but still major gaps in complication screening. BMJ Open Diabetes Research and Care, 2017, 5, e000459.	2.8	35
108	Intensive educational efforts combined with external quality assessment improve the preanalytical phase in general practitioner offices and nursing homes. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1857-1864.	2.3	6

#	Article	IF	CITATIONS
109	Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference. Clinical Chemistry and Laboratory Medicine, 2017, 55, 189-194.	2.3	130
110	Essential aspects of external quality assurance for point-of-care testing. Biochemia Medica, 2017, 27, 81-85.	2.7	10
111	Illness Perception and Psychological Distress in Persons with Porphyria Cutanea Tarda. Acta Dermato-Venereologica, 2016, 96, 674-678.	1.3	4
112	Lidar Uncertainty Measurement Experiment (LUMEX) – Understanding Sampling Errors. EPJ Web of Conferences, 2016, 119, 10004.	0.3	0
113	Effect of Participating in a Quality Improvement System over Time for Point-of-Care C-Reactive Protein, Glucose, and Hemoglobin Testing. Clinical Chemistry, 2016, 62, 1474-1481.	3.2	21
114	Initial Results from the Experimental Measurement Campaign (XMC) for Planetary Boundary Layer (PBL) Instrument Assessment (XPIA) Experiment. EPJ Web of Conferences, 2016, 119, 09004.	0.3	0
115	Biological Variation: The Effect of Different Distributions on Estimated Within-Person Variation and Reference Change Values. Clinical Chemistry, 2016, 62, 725-736.	3.2	94
116	Is D-dimer used according to clinical algorithms in the diagnostic work-up of patients with suspicion of venous thromboembolism? A study in six European countries. Thrombosis Research, 2016, 142, 1-7.	1.7	21
117	Sample collections from healthy volunteers for biological variation estimates' update: a new project undertaken by the Working Group on Biological Variation established by the European Federation of Clinical Chemistry and Laboratory Medicine, 2016, 54, 1599-1608.	2.3	76
118	Biomarker development targeting unmet clinical needs. Clinica Chimica Acta, 2016, 460, 211-219.	1.1	39
119	The variation in high sensitive cardiac troponin concentration during haemodialysis treatment is not similar to the biological variation observed in stable end stage renal disease patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 645-652.	1.2	10
120	Total error vs. measurement uncertainty: the match continues. Clinical Chemistry and Laboratory Medicine, 2016, 54, 195-6.	2.3	23
121	The Importance of Reagent Lot Registration in External Quality Assurance/Proficiency Testing Schemes. Clinical Chemistry, 2016, 62, 708-715.	3.2	27
122	8.3 External Quality Assurance for the Preanalytical Phase1., 2015, , 352-364.		0
123	Feasibility of using self-reported patient data in a national diabetes register. BMC Health Services Research, 2015, 15, 553.	2.2	29
124	Point-of-care urine albumin in general practice offices: effect of participation in an external quality assurance scheme. Clinical Chemistry and Laboratory Medicine, 2015, 53, 45-51.	2.3	9
125	Performance of 10 Systems for Self-Monitoring of Blood Glucose by Trained Healthcare Professionals and in the Hands of the Users. Clinical Chemistry, 2015, 61, 772-774.	3.2	12
126	Analytical performance specifications based on how clinicians use laboratory tests. Experiences from a post-analytical external quality assessment programme. Clinical Chemistry and Laboratory Medicine, 2015, 53, 857-62.	2.3	18

#	Article	IF	Citations
127	Proposal for the modification of the conventional model for establishing performance specifications. Clinical Chemistry and Laboratory Medicine, 2015, 53, 925-37.	2.3	22
128	Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry and Laboratory Medicine, 2015, 53, 833-5.	2.3	398
129	Biological variation – reliable data is essential. Clinical Chemistry and Laboratory Medicine, 2015, 53, 153-4.	2.3	34
130	A checklist for critical appraisal of studies of biological variation. Clinical Chemistry and Laboratory Medicine, 2015, 53, 879-85.	2.3	120
131	Setting analytical performance specifications based on outcome studies – is it possible?. Clinical Chemistry and Laboratory Medicine, 2015, 53, 841-8.	2.3	45
132	Benchmarking by HbA1c in a national diabetes quality register – does measurement bias matter?. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1433-9.	2.3	6
133	An international study of how laboratories handle and evaluate patient samples after detecting an unexpected APTT prolongation. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1593-603.	2.3	11
134	A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda. British Journal of Dermatology, 2015, 172, 223-229.	1.5	11
135	Egenkontroll av warfarinbehandling. Tidsskrift for Den Norske Laegeforening, 2015, 135, 849-853.	0.2	5
136	The influence of coagulation factors on the <i>in-treatment </i> biological variation of international normalized ratio for patients on warfarin. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 470-476.	1.2	7
137	Biological Variation of Hemoglobin A1c: Consequences for Diagnosing Diabetes Mellitus. Clinical Chemistry, 2014, 60, 1570-1572.	3.2	18
138	How to conduct External Quality Assessment Schemes for the pre-analytical phase?. Biochemia Medica, 2014, 24, 114-122.	2.7	36
139	How to achieve harmonisation of laboratory testing —The complete picture. Clinica Chimica Acta, 2014, 432, 8-14.	1.1	40
140	From biomarkers to medical tests: The changing landscape of test evaluation. Clinica Chimica Acta, 2014, 427, 49-57.	1.1	148
141	Albumin adsorption onto surfaces of urine collection and analysis containers. Clinica Chimica Acta, 2014, 431, 40-45.	1.1	7
142	Nursing home patients with diabetes: Prevalence, drug treatment and glycemic control. Diabetes Research and Clinical Practice, 2014, 105, 102-109.	2.8	41
143	Weekly and 90-Minute Biological Variations in Cardiac Troponin T and Cardiac Troponin I in Hemodialysis Patients and Healthy Controls. Clinical Chemistry, 2014, 60, 838-847.	3.2	77
144	Porfyrisykdommer i Norge. Tidsskrift for Den Norske Laegeforening, 2014, 134, 831-835.	0.2	22

#	Article	IF	Citations
145	Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA Journal, 2013, 4, 12.	6.1	53
146	A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and \hat{I}^3 -glutamyl transferase. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1997-2007.	2.3	74
147	The incidence of inherited porphyrias in Europe. Journal of Inherited Metabolic Disease, 2013, 36, 849-857.	3.6	220
148	Diagnosing Diabetes Mellitus: Performance of Hemoglobin A1c Point-of-Care Instruments in General Practice Offices. Clinical Chemistry, 2013, 59, 1790-1801.	3.2	42
149	Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria. Bioscience Reports, 2013, 33, .	2.4	25
150	External Quality Assessment of Point-of-Care Methods: Model For Combined Assessment of Method Bias and Single-Participant Performance by the Use of Native Patient Samples and Noncommutable Control Materials. Clinical Chemistry, 2013, 59, 363-371.	3.2	23
151	Preanalytical quality improvement: in quality we trust. Clinical Chemistry and Laboratory Medicine, 2013, 51, 229-241.	2.3	162
152	Week-to-Week Biological Variation in the N-terminal Prohormone of Brain Natriuretic Peptide in Hemodialysis Patients and Healthy Individuals. Clinical Chemistry, 2013, 59, 1813-1814.	3.2	4
153	Glucose meters – fit for clinical purpose. Clinical Chemistry and Laboratory Medicine, 2013, 51, 943-52.	2.3	16
154	Behandlingen av type 1-diabetes i spesialisthelsetjenesten – data fra Norsk diabetesregister for voksne. Tidsskrift for Den Norske Laegeforening, 2013, 133, 2257-2261.	0.2	23
155	A model for calculating the within-subject biological variation and likelihood ratios for analytes with a time-dependent change in concentrations; exemplified with the use of D-dimer in suspected venous thromboembolism in healthy pregnant women. Annals of Clinical Biochemistry, 2012, 49, 561-569.	1.6	15
156	How do laboratory specialists advise clinicians concerning the use and interpretation of renal tests?. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 143-151.	1.2	8
157	Effect of coagulation factors on discrepancies in International Normalized Ratio results between instruments. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1611-20.	2.3	10
158	External quality assessment of point-of-care International Normalized Ratio (INR) testing in Europe. Clinical Chemistry and Laboratory Medicine, 2012, 50, 81-8.	2.3	18
159	Selfâ€monitoring of blood glucose in patients with diabetes who do not use insulinâ€"are guidelines evidenceâ€based?. Diabetic Medicine, 2012, 29, 1226-1236.	2.3	18
160	Confidence Intervals and Power Calculations for Within-Person Biological Variation: Effect of Analytical Imprecision, Number of Replicates, Number of Samples, and Number of Individuals. Clinical Chemistry, 2012, 58, 1306-1313.	3.2	118
161	Calcium, Magnesium, Albumin, and Total Protein Measurement in Serum as Assessed with 20 Fresh-Frozen Single-Donation Sera. Clinical Chemistry, 2012, 58, 1597-1599.	3.2	21
162	Interpretation and management of INR results: A case history based survey in 13 countries. Thrombosis Research, 2012, 130, 309-315.	1.7	15

#	Article	IF	Citations
163	Increased yet iron-restricted erythropoiesis in postpartum mothers. Annals of Hematology, 2012, 91, 1435-1441.	1.8	5
164	Establishing a network of specialist Porphyria centres - effects on diagnostic activities and services. Orphanet Journal of Rare Diseases, 2012, 7, 93.	2.7	12
165	Fylkesvise forskjeller i salg av blodglukosestrimler og antidiabetika. Tidsskrift for Den Norske Laegeforening, 2012, 132, 1453-1456.	0.2	0
166	Preanalytical quality improvement: from dream to reality. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1113-26.	2.3	256
167	Laboratory investigation and follow-up of chronic kidney disease stage 3 in primary care. Clinica Chimica Acta, 2011, 412, 1138-1142.	1.1	6
168	Excess risk of adverse pregnancy outcomes in women with porphyria: a populationâ€based cohort study. Journal of Inherited Metabolic Disease, 2011, 34, 217-223.	3.6	27
169	Psychosocial Aspects of Predictive Genetic Testing for Acute Intermittent Porphyria in Norwegian Minors. JIMD Reports, 2011, 1, 1-7.	1.5	2
170	Effect of Ambient Temperature on Analytical Performance of Self-Monitoring Blood Glucose Systems. Diabetes Technology and Therapeutics, 2011, 13, 883-892.	4.4	38
171	Within-subject biological variation of glucose and HbA1c in healthy persons and in type 1 diabetes patients. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1501-7.	2.3	44
172	Do new concepts for deriving permissible limits for analytical imprecision and bias have any advantages over existing consensus?. Clinical Chemistry and Laboratory Medicine, 2011, 49, 637-640.	2.3	12
173	European Specialist Porphyria Laboratories: Diagnostic Strategies, Analytical Quality, Clinical Interpretation, and Reporting As Assessed by an External Quality Assurance Program. Clinical Chemistry, 2011, 57, 1514-1523.	3.2	38
174	Quality assurance of laboratory work and clinical use of laboratory tests in general practice in Norway: A survey. Scandinavian Journal of Primary Health Care, 2011, 29, 171-175.	1.5	5
175	Implementation of a method for glucose measurements in community pharmacies. International Journal of Pharmacy Practice, 2010, 18, 13-19.	0.6	6
176	Usefulness of factor V Leiden mutation testing in clinical practice. European Journal of Human Genetics, 2010, 18, 862-866.	2.8	13
177	Discrepancies in International Normalized Ratio Results between Instruments: A Model to Split the Variation into Subcomponents. Clinical Chemistry, 2010, 56, 1618-1626.	3.2	20
178	Can Changes in Troponin Results Be Useful in Diagnosing Myocardial Infarction?. Clinical Chemistry, 2010, 56, 1047-1049.	3.2	13
179	Self-monitoring of blood glucose with a focus on analytical quality: an overview. Clinical Chemistry and Laboratory Medicine, 2010, 48, 963-972.	2.3	14
180	Acute porphyrias may be overlooked in patients taking methenamine hippurate. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1355-7.	2.3	3

#	Article	IF	Citations
181	The Prevalence of Self-Monitoring of Blood Glucose and Costs of Glucometer Strips in a Nationwide Cohort. Diabetes Technology and Therapeutics, 2010, 12, 701-705.	4.4	18
182	Diagnosing microalbuminuria and consequences for the drug treatment of patients with type 2 diabetes: A European survey in primary care. Diabetes Research and Clinical Practice, 2010, 89, 103-109.	2.8	6
183	Quality assessment of patients´self-monitoring of blood glucose in community pharmacies. Pharmacy Practice, 2010, 8, 62-9.	1.5	9
184	Internal quality control of prothrombin time in primary care: comparing the use of patient split samples with lyophilised control materials. Thrombosis and Haemostasis, 2009, 102, 593-600.	3.4	5
185	Self-Monitoring of Blood Glucose in Type 1 Diabetes Patients with Insufficient Metabolic Control: Focused Self-Monitoring of Blood Glucose Intervention Can Lower Glycated Hemoglobin A1C. Journal of Diabetes Science and Technology, 2009, 3, 83-88.	2.2	42
186	Familial and Sporadic Porphyria Cutanea Tarda: Characterization and Diagnostic Strategies. Clinical Chemistry, 2009, 55, 795-803.	3.2	39
187	EFCC and Labs are Vital announce an Award for Outcomes Research in Laboratory Medicine. Clinical Chemistry and Laboratory Medicine, 2009, 47, .	2.3	0
188	Quality of Care for Patients With Type 2 Diabetes in Primary Care in Norway Is Improving: Results of cross-sectional surveys of 33 general practices in 1995 and 2005. Diabetes Care, 2009, 32, 81-83.	8.6	41
189	Maternal alcohol consumption. London Journal of Primary Care, 2009, 2, 28-35.	0.9	5
190	How to deal with semi-quantitative tests? Application of an ordinal scale model to measurements of urine glucose. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 662-672.	1,2	11
191	Peripheral leucocyte count variations in rectal cancer treatment. European Journal of Surgical Oncology, 2009, 35, 611-616.	1.0	5
192	Current Issues in Measurement and Reporting of Urinary Albumin Excretion. Clinical Chemistry, 2009, 55, 24-38.	3.2	298
193	How to deal with semi-quantitative tests? Application of an ordinal scale model to measurements of urine glucose. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 662-672.	1.2	1
194	Diabetes care in Norwegian pharmacies: a descriptive study. International Journal of Clinical Pharmacy, 2008, 30, 191-198.	1.4	12
195	Pharmacokinetics and Metabolism of the Antimalarial Piperaquine After Intravenous and Oral Single Doses to the Rat. Journal of Pharmaceutical Sciences, 2008, 97, 3400-3410.	3.3	25
196	Standardized Evaluation of Nine Instruments for Self-Monitoring of Blood Glucose. Diabetes Technology and Therapeutics, 2008, 10, 467-477.	4.4	49
197	Identifying acute porphyria in patients with acute polyneuropathy or encephalopathy. Nature Clinical Practice Neurology, 2008, 4, 648-649.	2.5	7
198	â€~Likelihood-ratio' and â€~odds' applied to monitoring of patients as a supplement to â€~reference chan value' (RCV). Clinical Chemistry and Laboratory Medicine, 2008, 46, 157-64.	ge 2.3	13

#	Article	IF	CITATIONS
199	How to deal with dichotomous tests? Application of a rankit ordinal scale model with examples from the Nordic ordinal scale project on screening tests. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 298-311.	1.2	9
200	Do Guidelines for the Diagnosis and Monitoring of Diabetes Mellitus Fulfill the Criteria of Evidence-Based Guideline Development?. Clinical Chemistry, 2008, 54, 1872-1882.	3.2	24
201	Postanalytical External Quality Assessment of Urine Albumin in Primary Health Care: An International Survey. Clinical Chemistry, 2008, 54, 1630-1636.	3.2	40
202	Response to Kitchen et al.'s External quality assessment of prothrombin time: The splitâ€sample model compared to external quality assessment with commercial control material. Scandinavian Journal of Clinical and Laboratory Investigation, 2007, 67, 676-677.	1.2	2
203	Clinical Diagnostic Technology-The Total Testing Process, Volume 3: The Postanalytical Phase. Kory M. Ward-Cook, Craig A. Lehmann, Larry E. Schoeff, and Robert H. Williams, eds. Washington, DC: AACC Press, 2006, 216 pp., \$65 (\$52.00 AACC members), softcover. ISBN 978-1-59425-055-2 Clinical Chemistry, 2007. 53. 1171-1172.	3.2	0
204	Point of Care Testing in the Diagnosis and Management of Diabetes. Point of Care, 2007, 6, 237-242.	0.4	0
205	Quality Assurance of Self-monitoring of Blood Glucose at the General Practitioner's Office. Point of Care, 2006, 5, 100-104.	0.4	3
206	Proficiency testing in analytical chemistry, microbiology and laboratory medicine – working group discussions on current status, problems and future directions. Accreditation and Quality Assurance, 2006, 11, 446-450.	0.8	2
207	Results and Feasibility of an External Quality Assessment Scheme for Self-Monitoring of Blood Glucose. Clinical Chemistry, 2006, 52, 1311-1317.	3.2	29
208	Postanalytical External Quality Assessment of Warfarin Monitoring in Primary Healthcare. Clinical Chemistry, 2006, 52, 1871-1878.	3.2	16
209	External quality assessment of prothrombin time: The splitâ€sample model compared with external quality assessment with commercial control material. Scandinavian Journal of Clinical and Laboratory Investigation, 2006, 66, 337-350.	1.2	18
210	Estimation and Application of Biological Variation of Urinary l´-Aminolevulinic Acid and Porphobilinogen in Healthy Individuals and in Patients with Acute Intermittent Porphyria. Clinical Chemistry, 2006, 52, 650-656.	3.2	51
211	European porphyria initiative (EPI): a platform to develop a common approach to the management of porphyrias and to promote research in the field. Physiological Research, 2006, 55 Suppl 2, S67-73.	0.9	7
212	Between-Lot Variation in External Quality Assessment of Glucose: Clinical Importance and Effect on Participant Performance Evaluation. Clinical Chemistry, 2005, 51, 1632-1636.	3.2	68
213	Postanalytical External Quality Assessment of Blood Glucose and Hemoglobin A1c: An International Survey. Clinical Chemistry, 2005, 51, 1145-1153.	3.2	33
214	Diagnosing Acute Porphyrias. Clinical Chemistry, 2004, 50, 803-805.	3.2	15
215	Standardized Evaluation of Instruments for Self-Monitoring of Blood Glucose by Patients and a Technologist. Clinical Chemistry, 2004, 50, 1068-1071.	3.2	67
216	Evidence-Based Guidelines in Laboratory Medicine: Principles and Methods. Clinical Chemistry, 2004, 50, 806-818.	3.2	65

#	Article	IF	Citations
217	Urine analysis and decision-making on cystitis in general practice. Scandinavian Journal of Clinical and Laboratory Investigation, 2004, 64, 729-736.	1.2	3
218	A multicentre study of reference intervals for haemoglobin, basic blood cell counts and erythrocyte indices in the adult population of the Nordic countries. Scandinavian Journal of Clinical and Laboratory Investigation, 2004, 64, 385-398.	1.2	79
219	Health technology assessment and implications for clinical practice: the case of prostate cancer screening. Scandinavian Journal of Clinical and Laboratory Investigation, 2003, 63, 331-338.	1.2	5
220	Die Onlay-Technik in der Hernienchirurgie der Narbenhernie. Visceral Medicine, 2003, 19, 35-38.	1.3	0
221	Haplotype Analysis of Norwegian and Swedish Patients with Acute Intermittent Porphyria (AIP): Extreme Haplotype Heterogeneity for the Mutation R116W. Disease Markers, 2003, 19, 41-46.	1.3	6
222	Instruments for Self-Monitoring of Blood Glucose: Comparisons of Testing Quality Achieved by Patients and a Technician. Clinical Chemistry, 2002, 48, 994-1003.	3.2	118
223	Interpretation of Hemoglobin A1c (HbA1c) Values among Diabetic Patients. Clinical Chemistry, 2001, 47, 1212-1217.	3.2	24
224	Patient-derived Quality Specifications for Instruments Used in Self-Monitoring of Blood Glucose. Clinical Chemistry, 2001, 47, 67-73.	3.2	56
225	Models for Combining Random and Systematic Errors. Assumptions and Consequences for different Models. Clinical Chemistry and Laboratory Medicine, 2001, 39, 589-95.	2.3	34
226	External quality assessment of general practice laboratories: organizational issues and interpretation of feedback reports. Scandinavian Journal of Clinical and Laboratory Investigation, 2001, 61, 103-110.	1.2	2
227	Influence of Index of Individuality on False Positives in Repeated Sampling from Healthy Individuals. Clinical Chemistry and Laboratory Medicine, 2001, 39, 160-5.	2.3	43
228	Automated counting of white and red blood cells in the cerebrospinal fluid. International Journal of Laboratory Hematology, 2000, 22, 203-210.	0.2	27
229	A Model for Setting Analytical Quality Specifications and Design of Control for Measurements on the Ordinal Scale. Clinical Chemistry and Laboratory Medicine, 2000, 38, 545-51.	2.3	16
230	Use and interpretation of HbA1ctesting in general practice. Implications for quality of care. Scandinavian Journal of Clinical and Laboratory Investigation, 2000, 60, 349-356.	1.2	17
231	Cobalamin Deficiency in General Practice. Assessment of the Diagnostic Utility and Cost-Benefit Analysis of Methylmalonic Acid Determination in Relation to Current Diagnostic Strategies. Clinical Chemistry, 1999, 45, 189-198.	3.2	87
232	The Index of Individuality Is Often a Misinterpreted Quantity Characteristic. Clinical Chemistry and Laboratory Medicine, 1999, 37, 655-61.	2.3	68
233	Circadian Variations in Human Peripheral Blood on Days With and Without Bone Marrow Sampling and Relation to Bone Marrow Cell Proliferation. Biological Rhythm Research, 1999, 30, 29-53.	0.9	6
234	The susceptibility to nephrotoxicity of streptozotocin-induced diabetic rats subchronically exposed to cadmium chloride in drinking water. Toxicology, 1999, 142, 69-75.	4.2	36

#	Article	IF	CITATIONS
235	External quality assurance of test requesting and test interpretation. Accreditation and Quality Assurance, 1999, 4, 414-415.	0.8	3
236	Quality specifications derived from objective analyses based upon clinical needs. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 531-534.	1.2	23
237	Withinâ€subject biological variation of reticulocytes and reticulocyteâ€derived parameters. European Journal of Haematology, 1998, 61, 42-48.	2.2	24
238	Systematic reviews of diagnostic testsâ€"a new challenge for laboratory medicine. Scandinavian Journal of Clinical and Laboratory Investigation, 1997, 57, 369-372.	1.2	8
239	Use and usefulness of laboratory handbooks. Scandinavian Journal of Clinical and Laboratory Investigation, 1997, 57, 647-653.	1.2	4
240	Systematic reviewing in laboratory medicine. Position Paper from the IFCC Committee on Systematic Reviewing in Laboratory Medicine. Journal of the International Federation of Clinical Chemistry, 1997, 9, 154-5.	0.1	5
241	Hyperkinetic or Attention Deficit Disorder. British Journal of Psychiatry, 1996, 169, 10-17.	2.8	58
242	Erythropoietic protoporphyria: two populations of reticulocytes, with and without protoporphyrin. European Journal of Clinical Investigation, 1996, 26, 270-278.	3.4	4
243	Is Placenta a Good Indicator of Cadmium and Lead Exposure?. Archives of Environmental Health, 1996, 51, 389-394.	0.4	44
244	Lead in Tissues of Deseased Lead Smelter Workers. Journal of Trace Elements in Medicine and Biology, 1995, 9, 136-143.	3.0	48
245	13. Psychosocial and environmental influences on upper respiratory symptomatology and the incidence of the †common cold' in children suffering from asthma. Biological Psychology, 1995, 41, 92.	2.2	0
246	Survey of office laboratory tests in general practice. Scandinavian Journal of Primary Health Care, 1994, 12, 77-83.	1.5	7
247	Near patient testing must improve patient care. Scandinavian Journal of Primary Health Care, 1994, 12, 65-67.	1.5	2
248	The erythrocyte sedimentation rate in general practice: Clinical assessment based on case histories. Scandinavian Journal of Clinical and Laboratory Investigation, 1994, 54, 291-300.	1.2	19
249	Decreased concentration of hemoglobin, accumulation of lipid oxidation products and unchanged skeletal muscle in Atlantic salmon (Salmo salar) fed low dietary vitamin E. Fish Physiology and Biochemistry, 1994, 12, 421-429.	2.3	44
250	Phenotyping autologous red cells within 1 day after allogeneic blood transfusion by using immunomagnetic isolation of reticulocytes. Transfusion, 1994, 34, 162-166.	1.6	6
251	HEMOGLOBIN OXYGEN AFFINITY IS INCREASED IN ERYTHROPOIETIC PROTOPORPHYRIA. Photochemistry and Photobiology, 1993, 57, 885-888.	2.5	7
252	Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal. Bulletin of Mathematical Biology, 1993, 55, 731-743.	1.9	41

#	Article	IF	Citations
253	6.1.2.1 Clinical Goals for Measurement of Hemoglobin in Primary Care as Assessed by Paper Vignettes. Upsala Journal of Medical Sciences, 1993, 98, 331-334.	0.9	O
254	Dry Chemistry Instruments in Primary Care. I. Operating Conditions and Financial Considerations. Family Practice, 1993, 10, 131-136.	1.9	0
255	High serum ferritin post partum: An acute phase reaction. Acta Obstetricia Et Gynecologica Scandinavica, 1993, 72, 50-51.	2.8	О
256	Dry Chemistry Instruments in Primary Care. I. Operating Conditions and Financial Considerations. Family Practice, 1993, 10, 124-130.	1.9	2
257	Circadian variation in serum cortisol and circulating neutrophils are markers for circadian variation of bone marrow proliferation in cancer patients. European Journal of Haematology, 1993, 50, 206-212.	2.2	17
258	Performance of the Reflotron and the Seralyzer in primary health care. Scandinavian Journal of Clinical and Laboratory Investigation, 1993, 53, 253-261.	1.2	1
259	Drinking habits and laboratory tests in seamen with and without chemical exposure Journal of Studies on Alcohol and Drugs, 1992, 53, 364-368.	2.3	5
260	A comprehensive multiple matrix model representing the life cycle of the tick that transmits agent of lyme disease. Journal of Theoretical Biology, 1992, 157, 203-220.	1.7	50
261	Mechanisms of photosensitivity in porphyric patients with special emphasis on erythropoietic protoporphyria. Journal of Photochemistry and Photobiology B: Biology, 1991, 10, 285-302.	3.8	53
262	Clinical assessment of haemoglobin values by general practitioners related to analytical and biological variation. Scandinavian Journal of Clinical and Laboratory Investigation, 1991, 51, 453-459.	1.2	32
263	Performance of Cell Counters in Primary Health Care. Scandinavian Journal of Primary Health Care, 1991, 9, 129-133.	1.5	5
264	ERYTHROPOIETIC PROTOPORPHYRIA: PHOTODYNAMIC TRANSFER OF PROTOPORPHYRIN FROM INTACT ERYTHROCYTES TO OTHER CELLS. Photochemistry and Photobiology, 1990, 51, 573-577.	2.5	28
265	A new method for isolation of reticulocytes: positive selection of human reticulocytes by immunomagnetic separation. Blood, 1990, 76, 2397-2403.	1.4	45
266	A new method for isolation of reticulocytes: positive selection of human reticulocytes by immunomagnetic separation. Blood, 1990, 76, 2397-2403.	1.4	12
267	Experiences with methods and equipment. Scandinavian Journal of Clinical and Laboratory Investigation, Supplement, 1990, 202, 42.	2.7	0
268	Implications of probability analysis for interpreting results of leukocyte esterase and nitrite test strips Clinical Chemistry, 1989, 35, 1663-1668.	3.2	27
269	Influence of lipid and leukocytes on the haemoglobin determination by Coulter Counter S Plus III, Technicon H 6000, Technicon H 1, LK 540, Reflotron and Hemocap. Scandinavian Journal of Clinical and Laboratory Investigation, 1989, 49, 145-148.	1.2	7
270	Mathematical formulation and studies of the risk parameters involved in HIV transmission. Bulletin of Mathematical Biology, 1989, 51, 467-474.	1.9	4

#	Article	IF	Citations
271	Mathematical formulation and studies of the risk parameters involved in HIV transmission. Bulletin of Mathematical Biology, 1989, 51, 467-474.	1.9	4
272	Performance of dry-chemistry instruments in primary health care. Scandinavian Journal of Clinical and Laboratory Investigation, 1989, 49, 483-488.	1.2	11
273	Management Training and Development: In Search of an Integrated Approach. Journal of General Management, 1989, 15, 69-82.	1.2	9
274	Performance of dry-chemistry instruments in primary health care. Scandinavian Journal of Clinical and Laboratory Investigation, 1989, 49, 483-488.	1.2	2
275	Light-induced redistribution and photobleaching of protoporphyrin in erythrocytes from patients with erythropoietic protoporphyria: An explanation of the rapid fading of fluorocytes. Journal of Photochemistry and Photobiology B: Biology, 1988, 2, 33-41.	3.8	12
276	Erythropoietic protoporphyria: A quantitative determination of erythrocyte protoporphyrin in individual cells by flow cytometry. Scandinavian Journal of Clinical and Laboratory Investigation, 1988, 48, 261-267.	1.2	16
277	Evaluation of Serum Separator Tubes as a Mail Transport Device in Primary Health Care. Scandinavian Journal of Primary Health Care, 1988, 6, 251-254.	1.5	1
278	Porphyrin-induced photodamage to isolated epidermal cells from hairless mice. Photo-dermatology, 1987, 4, 230-5.	0.1	0
279	Phototoxicity of tetracyclines as related to singlet oxygen production and uptake by polymorphonuclear leukocytes. Biochemical Pharmacology, 1986, 35, 2883-2885.	4.4	16
280	Stability of haematological constituents during simulated mail transport as measured by Coulter Counter S plus II or Technicon H 6000. Scandinavian Journal of Clinical and Laboratory Investigation, 1986, 46, 639-645.	1.2	1
281	Factors important for the measurement of chemiluminescence production by polymorphonuclear leukocytes. Journal of Immunological Methods, 1986, 88, 121-128.	1.4	49
282	Influence of tetracyclines and light on the release of lysozyme from human granulocytes and monocytes. International Journal of Immunopharmacology, 1986, 8, 875-880.	1.1	3
283	PHOTODYNAMIC RELEASE OF PROTOPORPHYRIN FROM INTACT ERYTHROCYTES IN ERYTHROPOIETIC PROTOPORPHYRIA: THE EFFECT OF SMALL REPETITIVE LIGHT DOSES. Photochemistry and Photobiology, 1985, 41, 535-541.	2.5	30
284	In vivo and in vitro effects of doxycycline on leucocyte membrane receptors. Clinical and Experimental Immunology, 1985, 62, 310-4.	2.6	4
285	Influence of tetracyclines on human polymorphonuclear leukocyte function. Antimicrobial Agents and Chemotherapy, 1984, 25, 354-357.	3.2	39
286	Effect of tetracyclines and UV light on oxygen consumption by human leukocytes. Antimicrobial Agents and Chemotherapy, 1984, 26, 489-492.	3.2	20
287	DOXYCYCLINE INDUCED PHOTODAMAGE TO HUMAN NEUTROPHILS AND TRYPTOPHAN. Photochemistry and Photobiology, 1984, 39, 43-48.	2.5	24
288	Influence of pH on porphyrin production in Propionibacterium acnes. Archives of Dermatological Research, 1984, 276, 396-400.	1.9	66

#	Article	IF	CITATIONS
289	Light-induced release of protoporphyrin, but not of zinc protoporphyrin, from erythrocytes in a patient with greatly elevated erythrocyte protoporphyrin. Blood, 1983, 62, 846-851.	1.4	20
290	Hematoporphyrin Derivative: Chemical Composition, Photochemical and Photosensitizing Properties. Advances in Experimental Medicine and Biology, 1983, 160, 165-179.	1.6	18
291	Exponential increase in age-specific prevalence of ventricular dysrhythmia among males. Journal of Chronic Diseases, 1982, 35, 743-750.	1.2	16
292	Effect of Doxycycline and PUVA Light on Human Polymorphonuclear Leukocyte Function., 1982,, 33-39.		6
293	Light-induced protoporphyrin release from erythrocytes in erythropoietic protoporphyria Journal of Clinical Investigation, 1982, 70, 693-698.	8.2	33
294	Porphyrin-induced photodamage at the cellular and the subcellular level as related to the solubility of the porphyrin. Clinica Chimica Acta, 1981, 109, 193-201.	1.1	98
295	Protoporphyrin-induced photodamage to mitochondria and lysosomes from rat liver. Clinica Chimica Acta, 1981, 111, 55-60.	1.1	27
296	Phototoxicity of protoporphyrin as related to its subcellular localization in mice livers after short-term feeding with griseofulvin. Biochemical Journal, 1981, 198, 67-74.	3.7	32
297	PORPHYRIN-INDUCED PHOTODAMAGE TO ISOLATED HUMAN NEUTROPHILS. Photochemistry and Photobiology, 1981, 34, 471-475.	2.5	21
298	PORPHYRIN-INDUCED PHOTODAMAGE TO ISOLATED HUMAN NEUTROPHILS. Photochemistry and Photobiology, 1981, 34, 471-475.	2.5	41
299	Porphyrin-induced photodamage to isolated human neutrophils. Photochemistry and Photobiology, 1981, 34, 471-5.	2.5	5
300	Zinc as an oral photoprotective agent in erythropoietic protoporphyria?. International Journal of Biochemistry & Cell Biology, 1980, 12, 931-934.	0.5	5
301	Porphyrin-sensitized photodynamic damage of isolated rat liver mitochondria. Biochimica Et Biophysica Acta - Bioenergetics, 1980, 593, 187-195.	1.0	59
302	Effect of zinc on protoporphyrin induced photohaemolysis. Scandinavian Journal of Clinical and Laboratory Investigation, 1980, 40, 185-189.	1.2	13
303	ADENYLATE KINASE IN NEUROLOGICAL DISEASES. Lancet, The, 1979, 314, 792-793.	13.7	6